Mainz Biomed NV
MYNZ
View Detailed Chart
0.945USD
-0.045-4.51%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.87MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.51%
5 Days
-20.55%
1 Month
-29.97%
6 Months
-35.69%
Year to Date
-15.59%
1 Year
-86.96%
View Detailed Chart
TradingKey Stock Score of Mainz Biomed NV
Currency: USD Updated: 2026-02-06Key Insights
Mainz Biomed NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 64 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Mainz Biomed NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Mainz Biomed NV Highlights
StrengthsRisks
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 68.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 893.99K.
Overvalued
The company’s latest PE is -0.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 529.42K shares, increasing 19.73% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+1314.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Mainz Biomed NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Mainz Biomed NV Info
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Ticker SymbolMYNZ
CompanyMainz Biomed NV
CEOBaechler (Guido)
Websitehttps://www.mainzbiomed.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69398.000
-572.130 (-0.82%)
282.580
+22.390 (+8.61%)
2092.560
+40.830 (+1.99%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
